Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0LDFQJ
ADC Name	H8R23-DT3C
Synonyms	H8R23 DT3C Click to Show/Hide
Drug Status	Investigative
Indication	In total 1 Indication(s) Non-small cell lung cancer [ICD11:2C25] Investigative
	3D MOL	2D MOL
Antibody Name	Anti-ANTXR2 mAb H8R23		Antibody Info
Antigen Name	Anthrax toxin receptor 2 (ANTXR2)		Antigen Info
Payload Name	Diphtheria toxin containing streptococcal protein G (DT3C)		Payload Info
Therapeutic Target	Eukaryotic elongation factor 2 (EEF2)		Target Info
Linker Name	Undisclosed

General Information of The Activity Data Related to This ADC

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 1 Activity Data Related to This Level

Standard Type	Value	Units	Cell Line	Disease Model
Tumor Growth Inhibition value (TGI)	≈ 85.9	%	Hs 746.T cells	Gastric adenocarcinoma

Full List of Activity Data of This Antibody-drug Conjugate

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 85.90% (Day 4)	High ANTXR2 expression (ANTXR2+++)
Method Description	The H8R23 mAb, or control IgG, and DT3C were incubated at room temperature for 30 min to generate a mAb-DT3C conjugate. Each conjugate theoretically consists of one mAb molecule (150 kDa) and two DT3Cs (140 kDa). Hs-746 T cells were seeded and incubated in the presence of the H8R23-DT3C conjugates or control IgG-DT3C conjugates (03 ug/mL each) for 96 h, then their viability and level of apoptosis were determined as described above. Click to Show/Hide
In Vitro Model	Gastric adenocarcinoma	Hs 746.T cells		CVCL_0333

References

Ref 1	Anthrax toxin receptor 2 is a potential therapeutic target for non-small cell lung carcinoma with MET exon 14 skipping mutations. Exp Cell Res. 2022 Apr 15;413(2):113078.